Prime Medicine, Inc. reported $4.6M of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $4.6M (to Q4 2025). Net income: −$188M, trailing twelve months to Q2 2026. Free cash flow: −$157M, trailing twelve months to Q2 2026. Operating margin: −4649%, trailing twelve months to Q4 2025.

PRMEPrime Medicine, Inc.

Healthcare

$3.58-39% 1Y

$3.58

$2.7052 weeks$6.45

PRME as reported

Prime Medicine, Inc. reported $4.6M of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed.

$4.6M

Revenue, trailing twelve months · to Q4 2025 · every figure below is as filed, with no scoring applied

Net income: −$188M
Net income · −5.7% year on year · trailing twelve months to Q2 2026
Free cash flow: −$157M
Free cash flow · +47% year on year · trailing twelve months to Q2 2026
Operating margin: −4649%
Operating margin · trailing twelve months to Q4 2025

Details›

Every series Ryufin has for PRME, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$4.6M	n/a	Q4 2025
Net income	−$188M	−5.7%	Q2 2026
EPS	−$1.08	−31%	Q2 2026
Operating margin	−4649%	n/a	Q4 2025
Net margin	−4478%	n/a	Q4 2025
ROE	−255%	n/a	Q2 2026
ROA	−63%	n/a	Q2 2026
Free cash flow	−$157M	+47%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.